Abstract
As a 50-year survivor of Hodgkin's lymphoma that was diagnosed and treated before computed tomography, positron-emission tomography (PET), splenectomies, and chemotherapy, I read with interest the article by Radford et al. (April 23 issue)1 and with skepticism the editorial2 on controversies in the treatment of early-stage Hodgkin's lymphoma. The conclusion of the editorialists that patients will need to choose “more certain absence of relapse” versus late-stage effects strikes me as unimaginable. I do not know what it would have meant to me in 1965 (at the age of 18 years) to be told I would later have thyroid cancer (at 60 years), breast cancer (at 63 years), and an aortic-valve replacement (at 66 years). No 18-year-old, healthy or unhealthy, imagines her life at the age of 68 years. I am grateful that as a member of the first cohort of cures, I was blissfully unaware for many years of my risks and extremely aware of my good fortune.3 I think most people will choose a greater certainty of cure over the uncertainty of future effects. If they live long enough to have sequelae, it may still seem like the right choice.

This publication has 3 references indexed in Scilit: